Recruiting Myelodysplastic Syndromes Studies in Cleveland
The Efficacy and Safety of Elritercept in Adult Participants With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) With Anemia (RENEW)
This study (KER-050-D301) is evaluating the efficacy and safety of elritercept (KER-050) versus placebo in adult participants with transfusion-dependent anemia with very low, low, or intermediate risk...
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)...
About Myelodysplastic Syndromes Clinical Trials in Cleveland
Myelodysplastic syndromes (MDS) are a group of cancers in which immature blood cells in the bone marrow do not mature properly. MDS can progress to acute myeloid leukemia. Treatments include growth factors, chemotherapy, and stem cell transplant.
There are currently 2 myelodysplastic syndromes clinical trials recruiting participants in Cleveland, OH. These studies are seeking a combined 311 participants. Research is being sponsored by Takeda, Rigel Pharmaceuticals. Clinical trial participation is free and participants receive study-related medical care at no cost.
Myelodysplastic Syndromes Clinical Trials in Cleveland — FAQ
Are there myelodysplastic syndromes clinical trials in Cleveland?
Yes, there are 2 myelodysplastic syndromes clinical trials currently recruiting in Cleveland, OH. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Cleveland?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Cleveland research site will contact you about next steps.
Are clinical trials in Cleveland free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Cleveland studies also compensate for your time and travel.
What myelodysplastic syndromes treatments are being tested?
The 2 active trials in Cleveland are testing new therapies including novel drugs, biologics, and treatment approaches for myelodysplastic syndromes.
Data updated March 2, 2026 from ClinicalTrials.gov